Agios Pharmaceuticals Inc
NASDAQ:AGIO
Relative Value
The Relative Value of one AGIO stock under the Base Case scenario is 25.95 USD. Compared to the current market price of 34.48 USD, Agios Pharmaceuticals Inc is Overvalued by 25%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
AGIO Competitors Multiples
Agios Pharmaceuticals Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Agios Pharmaceuticals Inc
NASDAQ:AGIO
|
1.9B USD | 71.9 | -5.5 | -3 | -2.9 | ||
US |
Abbvie Inc
NYSE:ABBV
|
287.1B USD | 5.3 | 60 | 12.9 | 19.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
168.4B USD | 6 | 25.1 | 18 | 27 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
103.5B USD | 7.9 | 26.2 | 17.6 | 19.3 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.4B USD | 10.5 | 28.6 | 22.8 | 23.9 | ||
AU |
CSL Ltd
ASX:CSL
|
133.2B AUD | 6.2 | 35.6 | 21.6 | 26.7 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.3B USD | 2.9 | 166 | 6.7 | 8.7 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
46.9B USD | 6.9 | -10 | -10.8 | -9.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.5B USD | 3.3 | 27 | 13.8 | 17.3 | ||
KR |
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |